Mark Cuban’s Cost Plus Drugs is getting a lot of attention—and not all of it is flattering.
In a recent piece from DrugPatentWatch, the argument is blunt: “Cost Plus Drugs is killing spread pricing.” The claim lands because it touches a nerve in U.S. h…
Mark Cuban’s Cost Plus Drugs Is Killing Spread Pricing — Here’s What That Actually Means Read Post »
Cost-plus works—until it doesn’t. The Cuban model is a masterclass in generics economics, and a warning label for brand pricing.
There’s a reason “cost-plus” keeps showing up in policy debates: it sounds like the antidote to runaway drug prices. Pay fo…
Drug pricing is a black box—until you look at the math.
Most people think prescription drug costs are set by “market forces.” But if you’ve ever wondered why two drugs that treat the same condition can carry wildly different price tags, the answer ofte…
How Cost Plus Drugs Exposes Drug Pricing Secrets Your Competitors Don’t Want You to Know Read Post »
Mark Cuban’s generic-drug play isn’t just another “disrupt healthcare” headline. It’s a bet on a painfully specific weak point in the pharmaceutical value chain: the moment a brand’s patent moat starts to crumble—and the market’s incentives still haven…
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First? Read Post »
Biotech hiring isn’t just a talent story—it’s a patent story.
If you’ve been watching the market closely, you’ve probably noticed a pattern: certain roles start showing up before major deal headlines. Teams get staffed ahead of time. Legal and business…
Patent Deals Predict Biotech Hiring: How to Read Licensing Signals Before the Jobs Post Read Post »
Pharma’s “patent cliff” isn’t a cliff anymore. It’s a treadmill.
If you’ve worked anywhere near drug pricing, you’ve seen the pattern: a blockbuster’s exclusivity window starts to narrow, revenue projections get stress-tested, and then—almost like cloc…
Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs Read Post »
Drug pricing transparency is having a moment. In boardrooms and policy circles, the idea sounds almost irresistible: shine a light on how much companies charge, how much they spend, and how pricing decisions are made—then let “the market” and “public s…
Drug Pricing Transparency Is More Dangerous Than Price Cuts Read Post »
Mark Cuban’s “cost-plus” pitch is more than a consumer-friendly headline—it’s a live stress test of how the U.S. drug market actually prices risk, allocates capital, and defends margins.
And if you’re an operator, investor, or policy-minded leader, you…
Pharma doesn’t “miss” patent dates. It just doesn’t miss them publicly.
Behind every headline about a blockbuster’s next extension window is a quieter, more technical story: how companies track IND and NDA timelines across jurisdictions to position pat…
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
Pharma doesn’t “miss” patent dates. It just doesn’t let you see how early the clock starts.
In the race to secure global exclusivity, the real contest isn’t only about what’s in the patent office—it’s about what’s happening behind the scenes long befor…
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
Get new actionable insights and updates from BiotechBlog
